Personalized key unlocking cancer resistance pathways in lung

Cracking Cancer Resistance: How New Research is Personalizing Lung Cancer Treatment

Rhea Morgan monogram
Rhea Morgan in Health & Wellness October 2026 • 5 min read.

"Unveiling the complexities of drug resistance in lung cancer, and how personalized approaches using advanced proteomics are paving the way for more effective therapies."


Lung cancer remains a leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) being the most common type. While treatments targeting the epidermal growth factor receptor (EGFR) have shown initial success, resistance to these therapies inevitably emerges, limiting long-term survival. This resistance is a complex puzzle, driven by various mechanisms that allow cancer cells to bypass the intended effects of the drugs.

Traditional research approaches often focus on identifying common resistance pathways, potentially overlooking the unique adaptations that occur in individual tumors. This 'one-size-fits-all' approach may explain why some treatments succeed while others fail, even among patients with seemingly similar cancer profiles.

Now, groundbreaking research is shifting the focus towards personalized strategies that account for the individual characteristics of each tumor. By employing advanced proteomic techniques, scientists are mapping the intricate signaling networks within resistant tumors, revealing both shared and unique mechanisms that drive treatment failure. This deeper understanding is paving the way for more tailored and effective therapies.

AI Search Multiple angles on this topic

Why Resistance Matters

Lung cancer remains a major health challenge, and treatment outcomes can vary substantially between patients. Resistance may develop as tumors change during treatment, limiting the durability of initially effective therapies. These challenges have increased interest in approaches that match treatment more closely to each tumor's biology.

Established Treatments and Their Limits

Standard lung cancer care may include chemotherapy, radiotherapy, surgery, and targeted medicines selected according to tumor characteristics. Reviews emphasize that molecular mutations can guide targeted treatment, but targeted medicines also have disadvantages and may lose effectiveness as resistance develops. Research has linked gene mutations to drug resistance, although the genetic background associated with sensitivity to platinum drugs in small-cell lung cancer remains unclear.

From Targeted Therapy to Resistance Biology

Targeted therapies produced major benefits in cancers such as chronic myelogenous leukemia, colon cancer, and breast cancer, but their benefits in lung cancer have been limited in part by drug resistance. Later work on lung cancer immunotherapy has focused on clinical milestones as well as intrinsic and extrinsic resistance mechanisms. Research on lung adenocarcinoma has also emphasized that understanding the cell of origin and molecular changes during tumor progression could support better therapeutic strategies.

Decoding Tumor Resistance: A Personalized Approach

Personalized key unlocking cancer resistance pathways in lung

Researchers at Massachusetts Institute of Technology delved into the mechanisms of resistance to two promising NSCLC treatments: osimertinib, a third-generation EGFR inhibitor, and JNJ-61186372, an EGFR/Met bispecific antibody. Their goal was to identify the molecular changes that enable cancer cells to survive and thrive despite these targeted therapies.

The team established four NSCLC xenograft models, each representing different EGFR mutation profiles and Met pathway activation levels, mirroring the diverse landscape of clinical NSCLC cases. These models were then treated with osimertinib or JNJ-61186372, and the resulting resistant tumors were analyzed using quantitative mass spectrometry-based proteomics. This powerful technique allowed them to map the phosphotyrosine signaling pathways within the tumors, providing a detailed snapshot of the active signaling networks.

  • Uncovering Unique Resistance Patterns: The proteomic analysis revealed a surprising degree of heterogeneity among the resistant tumors. While some common resistance mechanisms were observed, each tumor also displayed a unique signaling profile, indicating that cancer cells can adapt to treatment in a variety of ways.
  • The Role of Met and Bypass Signaling: In some resistant tumors, the Met pathway was found to be upregulated, suggesting that activation of this alternative signaling route can bypass EGFR inhibition and promote continued growth. Other tumors exhibited increased phosphorylation of EGFR and/or ErbB family members, indicating plasticity within these receptor tyrosine kinases (RTKs).
  • Downregulation of EGFR and SFK Signaling: Despite the emergence of resistance, the researchers found that both EGFR and Src family kinase (SFK) signaling networks were generally downregulated in resistant tumors. This seemingly paradoxical finding suggests that cancer cells can survive even when their primary growth pathways are inhibited, highlighting the adaptability of these cells.
AI Search Multiple angles on this topic

Personalized Medicine in Current Research

A 2025 review examines current therapeutic approaches across lung cancer types and highlights emerging therapies intended to improve treatment precision. It presents personalized medicine as a way to enhance treatment outcomes and patients' quality of life. The review also considers how newer approaches may extend beyond conventional treatment strategies.

Why Personalization Is Not a Guarantee

Personalized treatment does not eliminate the biological complexity of lung cancer or guarantee a durable response. Tumors can change during therapy, and resistance may emerge even when treatment is initially matched to a detected feature. As a result, early research findings and individualized strategies should be interpreted cautiously rather than treated as universally effective.

Comparing Treatment Strategies

Research comparing conventional and personalized approaches shows that treatment selection must account for more than a single molecular alteration. Non-oncogene-targeting therapies, including DNA replication inhibitors and cytoskeletal function inhibitors, are being considered within personalized medicine, but they also have limitations and resistance factors. In advanced lung adenocarcinoma, resistance to EGFR tyrosine kinase inhibitors is common enough that subsequent treatment strategies can remain uncertain.

Importantly, the researchers discovered that combining EGFR inhibition with SFK inhibition could enhance cell killing in vitro. This finding suggests that residual SFK signaling may contribute to therapeutic resistance and that targeting this pathway in combination with EGFR inhibitors could delay or overcome resistance.

The Future of Lung Cancer Treatment: Personalized Strategies and Combination Therapies

This research underscores the need for personalized approaches to lung cancer treatment. By identifying the unique resistance mechanisms that drive tumor growth in individual patients, clinicians can tailor therapies to target the specific vulnerabilities of each cancer.

AI Search Multiple angles on this topic

A More Adaptive Treatment Model

The broader direction of lung cancer research is toward treatment decisions that reflect the biology of an individual tumor. Personalization may help clinicians respond to differences in mutations, tumor evolution, and treatment resistance. However, its value depends on evidence, careful interpretation, and the ability to adapt when the disease changes.

Where Research May Go Next

Future research is likely to focus on detecting resistance earlier and identifying treatment strategies that remain effective as tumors evolve. Investigators may also explore how repeated molecular assessment can guide changes in therapy. These possibilities are promising, but their clinical value will need to be established through further research.

Challenges Beyond the Tumor

Personalized lung cancer treatment must operate within real-world health systems that differ in diagnostic resources, treatment access, and clinical expertise. The complexity of tumor biology can make testing and treatment decisions difficult even when relevant technologies exist. These practical factors may influence how consistently research advances translate into patient care.

Personalization in Practice

A 2026 case report described an advanced lung adenocarcinoma with an EGFR exon 21 L858R mutation in which organoid-guided personalized therapy produced a partial response in the lung lesion after multiple prior systemic treatments had failed. Another 2025 study analyzed whether a universal computational system could predict treatment benefit using systemic treatment lines from a real-world lung cancer cohort. These reports illustrate both the potential of individualized treatment and the importance of evaluating it in patients whose disease has already shown resistance.

The study also highlights the potential of combination therapies. By simultaneously inhibiting multiple signaling pathways, such as EGFR and SFK, it may be possible to overcome resistance and achieve more durable responses.

While further research is needed to translate these findings into clinical practice, this study represents a significant step towards a future where lung cancer treatment is more effective and personalized.

Osimertinib survival against earlier EGFR inhibitors

  • 18.9Median progression-free survival was 18.9 months with first-line osimertinib, compared with 10.2 months with earlier-generation EGFR tyrosine kinase inhibitors.[1]

How resistance reports compare across treatment settings

Among patients who developed progressive disease after osimertinib, C757S was reported in 21.5%; a separate report found C797S or other secondary EGFR mutations in 7% of patients in the FLAURA and ORCHARD series. These percentages concern different mutation groupings and settings, so they are not a direct like-for-like comparison.[2] [3]

A phase III trial compared osimertinib plus savolitinib with platinum-based chemotherapy in patients with MET amplification acquired after first-line EGFR TKI therapy; the cited material describes the comparison but does not report its outcomes.[4]

What resistance testing still needs to resolve

  • How often do tissue and plasma testing identify the same resistance features, given that MET amplification was sometimes found only in tissue?[3]
  • What resistance mechanisms remain when genetic analysis does not detect a cause, including mechanisms beyond standard genetic analysis or those missed by plasma testing?[5] [6]
  • How frequently does resistance involve transformation into a different histological subtype, and how reliably can testing detect that change?[3] [7] [8]

Sources

  1. Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer (pmc.ncbi.nlm.nih.gov)
  2. Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis (pmc.ncbi.nlm.nih.gov)
  3. Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer (pmc.ncbi.nlm.nih.gov)
  4. Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance (pmc.ncbi.nlm.nih.gov)
  5. Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development (pmc.ncbi.nlm.nih.gov)
  6. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON (pmc.ncbi.nlm.nih.gov)
  7. Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients (pmc.ncbi.nlm.nih.gov)
  8. A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

Why do lung cancer treatments sometimes stop working, and what's being done to address this resistance?

Resistance to lung cancer treatments like EGFR inhibitors occurs because cancer cells adapt through various mechanisms, bypassing the intended drug effects. Traditional research often focuses on common pathways, but personalized strategies using advanced proteomics aim to identify the unique adaptations in individual tumors. By mapping signaling networks, researchers can reveal both shared and unique resistance mechanisms, paving the way for more tailored therapies. This shift acknowledges that a 'one-size-fits-all' approach might not work due to the diverse nature of tumor resistance.

2

How did researchers at MIT study resistance to lung cancer drugs like osimertinib and JNJ-61186372?

Researchers at MIT used NSCLC xenograft models with different EGFR mutation profiles and Met pathway activation levels to study resistance to osimertinib and JNJ-61186372. They treated these models with the drugs and then analyzed the resistant tumors using quantitative mass spectrometry-based proteomics. This technique allowed them to map the phosphotyrosine signaling pathways within the tumors, giving them a detailed look at the active signaling networks. By understanding these pathways, they could identify how cancer cells survive despite targeted therapies.

3

What did proteomic analysis reveal about the different ways lung tumors become resistant to treatment?

Proteomic analysis of resistant tumors revealed significant heterogeneity, with each tumor displaying a unique signaling profile alongside some common resistance mechanisms. The Met pathway was often upregulated, suggesting it can bypass EGFR inhibition. Increased phosphorylation of EGFR and ErbB family members also indicated plasticity within receptor tyrosine kinases (RTKs). Paradoxically, EGFR and Src family kinase (SFK) signaling were generally downregulated, showing cancer cells can survive even when primary growth pathways are inhibited. This adaptability emphasizes the complexity of lung cancer resistance.

4

Why is combining EGFR inhibition with SFK inhibition a promising strategy for lung cancer treatment?

The finding that combining EGFR inhibition with SFK inhibition could enhance cell killing in vitro suggests that residual SFK signaling contributes to therapeutic resistance. Targeting the SFK pathway alongside EGFR inhibitors could delay or overcome resistance. This combined approach highlights the potential of personalized strategies to address the unique vulnerabilities of individual tumors, ultimately improving treatment outcomes for lung cancer patients. Future research will likely focus on identifying specific SFK inhibitors that are most effective in combination with EGFR inhibitors for different NSCLC subtypes.

5

What are personalized approaches to lung cancer treatment, and how might they improve patient outcomes?

Personalized approaches to lung cancer treatment involve identifying the unique resistance mechanisms driving tumor growth in individual patients. Clinicians can then tailor therapies to target the specific vulnerabilities of each cancer. This strategy requires advanced diagnostic techniques like proteomics to map tumor signaling networks and understand the specific adaptations that enable resistance. By moving away from a 'one-size-fits-all' approach and towards personalized combination therapies, there is hope for significantly improving outcomes in lung cancer treatment, especially for those with non-small cell lung cancer (NSCLC).

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.